Hormone Receptor, HER2/NEU and EGFR Expression in Ovarian Carcinoma - is here a Prognostic Phenotype?

Purpose: We aimed to evaluate the effects of hormone receptor, HER2, and epidermal growth factor receptor(EGFR) expression on epithelial ovarian cancer (EOC) prognosis and investigate whether or not phenotypicsubtypes might exist. Materials and
Methods: The medical records of 82 patients who were diagnosed with EOCbetween 2003 and 2012 and treated by platinum-based chemotherapy were retrospectively evaluated. Expressionof EGFR, oestrogen (ER), progesterone (PR), and cerbB2 (HER2) receptors were assessed immunohistochemicallyon paraffin-embedded tissues of these patients. Three phenotypic subtypes were defined according to ER, PR,and HER2 expression and associations of these with EGFR expression, clinicopathologic features, platinumsensitivity, and survival were investigated.
Results: When we classified EOC patients into three subtypes,63.4% had hormone receptor positive (HR(+)) (considering breast cancer subtypes, luminal A), 18.3% hadtriple negative, and 18.3% had HER2(+) disease. EGFR positivity was observed in 37 patients (45.1%) and wassignificantly more frequent with advanced disease (p=0.013). However, no significant association with otherclinicopathologic features and platinum sensitivity was observed. HER2(+) patients had significantly pooreroutcomes than HER2(-) counterparts (triple negative and HR positive patients) (p=0.019). Multivariate analysisdemonstrated that the strongest risk factor for death was residual disease after primary surgery.
Conclusions:Triple negative EOC may not be an aggressive phenotype as in breast cancer. The HER2 positive EOC has moreaggressive behaviour compared to triple negative and HR(+) phenotypes. EGFR expression is more frequentin advanced tumours, but is not related with poorer outcome. Additional ovarian cancer molecular subtypingusing gene expression analysis may provide more reliable data.